Compare Gilead Sciences, Inc. (GILD) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Mercadolibre Inc — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while Mercadolibre Inc trades at $1,900.1 (market cap $94.13B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Mercadolibre Inc for 117 Days on average.
| GILD | MELI | |
|---|---|---|
Market Cap | $182.40B | $94.13B |
Volume | 4,469,821 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $2.36K |
52-Week Low | $116.74 | $1.55K |
Typical Hold Time | 111 Days | 117 Days |
Enterprise Value | $205.46B | $101.77B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
MercadoLibre (MELI) trades at $1,873.57, up 0.04% on the day, with a bullish technical signal from moving averages and strong support near $1,813. The company reported $28.89B revenue in 2025, though net income margin dipped to 6.91%, and recent earnings show mixed results with a beat in Q2 2026 but misses in prior quarters. Analyst consensus is strongly positive with a $2,170 price target, and cash flow from operations surged to $12.12B in 2025, underscoring robust financial health.
Outlook remains favorable due to dominant e-commerce and fintech positioning in Latin America, with revenue projected to hit $35.2B in 2026. Risks include profit margin pressures and macroeconomic volatility in key markets like Argentina. Institutional sentiment is bullish, with 73% of analysts rating it Buy, supporting potential upside near all-time highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
